These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 11044213)

  • 21. Loganin attenuates diabetic nephropathy in C57BL/6J mice with diabetes induced by streptozotocin and fed with diets containing high level of advanced glycation end products.
    Liu K; Xu H; Lv G; Liu B; Lee MK; Lu C; Lv X; Wu Y
    Life Sci; 2015 Feb; 123():78-85. PubMed ID: 25623853
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy.
    Forbes JM; Thorpe SR; Thallas-Bonke V; Pete J; Thomas MC; Deemer ER; Bassal S; El-Osta A; Long DM; Panagiotopoulos S; Jerums G; Osicka TM; Cooper ME
    J Am Soc Nephrol; 2005 Aug; 16(8):2363-72. PubMed ID: 15930093
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Polydatin promotes Nrf2-ARE anti-oxidative pathway through activating Sirt1 to resist AGEs-induced upregulation of fibronetin and transforming growth factor-β1 in rat glomerular messangial cells.
    Huang K; Chen C; Hao J; Huang J; Wang S; Liu P; Huang H
    Mol Cell Endocrinol; 2015 Jan; 399():178-89. PubMed ID: 25192797
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mesangial cells from diabetic NOD mice constitutively express increased density of atrial natriuretic peptide C receptors.
    Ardaillou N; Placier S; Striker L; Striker G; Ardaillou R
    Kidney Int; 1999 Apr; 55(4):1293-302. PubMed ID: 10200993
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ribozyme targeting of receptor for advanced glycation end products in mouse mesangial cells.
    Tsuji H; Iehara N; Masegi T; Imura M; Ohkawa J; Arai H; Ishii K; Kita T; Doi T
    Biochem Biophys Res Commun; 1998 Apr; 245(2):583-8. PubMed ID: 9571198
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Meprin-alpha in chronic diabetic nephropathy: interaction with the renin-angiotensin axis.
    Mathew R; Futterweit S; Valderrama E; Tarectecan AA; Bylander JE; Bond JS; Trachtman H
    Am J Physiol Renal Physiol; 2005 Oct; 289(4):F911-21. PubMed ID: 15942051
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of receptors for advanced glycosylated end-products in renal disease.
    Abel M; Ritthaler U; Zhang Y; Deng Y; Schmidt AM; Greten J; Sernau T; Wahl P; Andrassy K; Ritz E
    Nephrol Dial Transplant; 1995; 10(9):1662-7. PubMed ID: 8559486
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Macrophage scavenger receptor-a-deficient mice are resistant against diabetic nephropathy through amelioration of microinflammation.
    Usui HK; Shikata K; Sasaki M; Okada S; Matsuda M; Shikata Y; Ogawa D; Kido Y; Nagase R; Yozai K; Ohga S; Tone A; Wada J; Takeya M; Horiuchi S; Kodama T; Makino H
    Diabetes; 2007 Feb; 56(2):363-72. PubMed ID: 17259380
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease.
    Tanji N; Markowitz GS; Fu C; Kislinger T; Taguchi A; Pischetsrieder M; Stern D; Schmidt AM; D'Agati VD
    J Am Soc Nephrol; 2000 Sep; 11(9):1656-1666. PubMed ID: 10966490
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of the advanced glycation end-product receptor complex in human vascular endothelial cells.
    Stitt AW; He C; Vlassara H
    Biochem Biophys Res Commun; 1999 Mar; 256(3):549-56. PubMed ID: 10080935
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advanced glycation end products mediated cellular and molecular events in the pathology of diabetic nephropathy.
    Kumar Pasupulati A; Chitra PS; Reddy GB
    Biomol Concepts; 2016 Dec; 7(5-6):293-309. PubMed ID: 27816946
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pigment epithelium-derived factor (PEDF) inhibits proximal tubular cell injury in early diabetic nephropathy by suppressing advanced glycation end products (AGEs)-receptor (RAGE) axis.
    Maeda S; Matsui T; Takeuchi M; Yoshida Y; Yamakawa R; Fukami K; Yamagishi S
    Pharmacol Res; 2011 Mar; 63(3):241-8. PubMed ID: 21115116
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice.
    Fan Q; Liao J; Kobayashi M; Yamashita M; Gu L; Gohda T; Suzuki Y; Wang LN; Horikoshi S; Tomino Y
    Nephrol Dial Transplant; 2004 Dec; 19(12):3012-20. PubMed ID: 15574998
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Extracellular matrix is modulated in advanced glycation end products milieu via a RAGE receptor dependent pathway boosted by transforming growth factor-β1 RAGE.
    Serban AI; Stanca L; Geicu OI; Munteanu MC; Costache M; Dinischiotu A
    J Diabetes; 2015 Jan; 7(1):114-24. PubMed ID: 24666836
    [TBL] [Abstract][Full Text] [Related]  

  • 35. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy.
    Wendt TM; Tanji N; Guo J; Kislinger TR; Qu W; Lu Y; Bucciarelli LG; Rong LL; Moser B; Markowitz GS; Stein G; Bierhaus A; Liliensiek B; Arnold B; Nawroth PP; Stern DM; D'Agati VD; Schmidt AM
    Am J Pathol; 2003 Apr; 162(4):1123-37. PubMed ID: 12651605
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential expression of receptors for advanced glycation end-products in peritoneal mesothelial cells exposed to glucose degradation products.
    Lai KN; Leung JC; Chan LY; Li FF; Tang SC; Lam MF; Tse KC; Yip TP; Chan TM; Wieslander A; Vlassara H
    Clin Exp Immunol; 2004 Dec; 138(3):466-75. PubMed ID: 15544624
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Linagliptin blocks renal damage in type 1 diabetic rats by suppressing advanced glycation end products-receptor axis.
    Nakashima S; Matsui T; Takeuchi M; Yamagishi SI
    Horm Metab Res; 2014 Sep; 46(10):717-21. PubMed ID: 24710699
    [TBL] [Abstract][Full Text] [Related]  

  • 38. RAGE Deletion Confers Renoprotection by Reducing Responsiveness to Transforming Growth Factor-β and Increasing Resistance to Apoptosis.
    Hagiwara S; Sourris K; Ziemann M; Tieqiao W; Mohan M; McClelland AD; Brennan E; Forbes J; Coughlan M; Harcourt B; Penfold S; Wang B; Higgins G; Pickering R; El-Osta A; Thomas MC; Cooper ME; Kantharidis P
    Diabetes; 2018 May; 67(5):960-973. PubMed ID: 29449307
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of megsin mRNA, a novel mesangium-predominant gene, in the renal tissues of various glomerular diseases.
    Suzuki D; Miyata T; Nangaku M; Takano H; Saotome N; Toyoda M; Mori Y; Zhang SY; Inagi R; Endoh M; Kurokawa K; Sakai H
    J Am Soc Nephrol; 1999 Dec; 10(12):2606-13. PubMed ID: 10589701
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of Smad1 in diabetic nephropathy: Molecular mechanisms and implications as a diagnostic marker.
    Abe H; Matsubara T; Arai H; Doi T
    Histol Histopathol; 2011 Apr; 26(4):531-41. PubMed ID: 21360446
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.